Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a percutaneous c...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
KAI Pharmaceuticals
Collaborators
NCT07478003 · STEMI - ST Elevation Myocardial Infarction
NCT07547098 · Cardiovascular Diseases (CVD), Chronic Kidney Disease, and more
NCT07142265 · Myocardial Infarction
NCT06939738 · Acute Myocardial Infarction (AMI)
NCT05168462 · Cardiogenic Shock, Myocardial Infarction
Huntsville, Alabama
Escondido, California
Torrance, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions